BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-1.98%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$4.46B
AUM Growth
+$4.46B
(-14%)
Cap. Flow
-$467M
Cap. Flow
% of AUM
-10.47%
Top 10 Holdings %
Top 10 Hldgs %
48.58%
Holding
170
New
10
Increased
26
Reduced
81
Closed
22
Top Buys
| 1 |
Akero Therapeutics
AKRO
|
$50.6M |
| 2 |
AbbVie
ABBV
|
$18.9M |
| 3 |
Stryker
SYK
|
$17.3M |
| 4 |
Beam Therapeutics
BEAM
|
$17.1M |
| 5 |
Baxter International
BAX
|
$15.6M |
Top Sells
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$204M |
| 2 |
Arvinas
ARVN
|
$45.8M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$36.1M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$32.2M |
| 5 |
Tandem Diabetes Care
TNDM
|
$28.2M |
Sector Composition
| 1 | Healthcare | 99.87% |
| 2 | Technology | 0.01% |
| 3 | Communication Services | 0.01% |
| 4 | Consumer Discretionary | 0% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
argenx
ARGX
$43.6B
| $343M | 7.68% | 578,874 -14,310 | -2% | -$8.47M |
|
2
Ionis Pharmaceuticals
IONS
$6.79B
| $237M | 5.31% | 7,853,198 -15,502 | -0.2% | -$468K |
|
|
3
Stryker
SYK
$150B
| $211M | 4.73% | 566,597 +46,571 | +9% | +$17.3M |
|
4
Intuitive Surgical
ISRG
$170B
| $211M | 4.72% | 425,746 -38,631 | -8% | -$19.1M |
|
5
Alnylam Pharmaceuticals
ALNY
$58.5B
| $207M | 4.65% | 768,147 -2,121 | -0.3% | -$573K |
|
6
Abbott
ABT
$231B
| $206M | 4.63% | 1,556,129 -132,531 | -8% | -$17.6M |
|
7
Neurocrine Biosciences
NBIX
$13.8B
| $201M | 4.51% | 1,820,000 | – | – |
|
|
8
Vertex Pharmaceuticals
VRTX
$100B
| $200M | 4.49% | 413,071 -74,363 | -15% | -$36.1M |
|
9
Boston Scientific
BSX
$156B
| $197M | 4.41% | 1,951,020 -184,275 | -9% | -$18.6M |
|
10
Revolution Medicines
RVMD
$7.1B
| $155M | 3.47% | 4,374,300 -12,600 | -0.3% | -$446K |
|
11
Incyte
INCY
$16.5B
| $127M | 2.84% | 2,091,780 -65,698 | -3% | -$3.98M |
|
12
Agios Pharmaceuticals
AGIO
$2.19B
| $103M | 2.31% | 3,515,150 | – | – |
|
13
UnitedHealth
UNH
$281B
| $86.3M | 1.93% | 164,742 +5,029 | +3% | +$2.63M |
|
14
Medtronic
MDT
$119B
| $84.3M | 1.89% | 938,355 -104,593 | -10% | -$9.4M |
|
15
Scholar Rock
SRRK
$3.14B
| $80.6M | 1.81% | 2,506,890 -3,800 | -0.2% | -$122K |
|
16
Becton Dickinson
BDX
$55.3B
| $78.9M | 1.77% | 344,311 +6,763 | +2% | +$1.55M |
|
17
DexCom
DXCM
$29.5B
| $72.7M | 1.63% | 1,064,108 +19,064 | +2% | +$1.3M |
|
18
Insulet
PODD
$23.9B
| $71.2M | 1.6% | 271,286 -50,631 | -16% | -$13.3M |
|
19
Edwards Lifesciences
EW
$47.8B
| $70.4M | 1.58% | 971,969 -125,879 | -11% | -$9.12M |
|
20
Celldex Therapeutics
CLDX
$1.47B
| $55.7M | 1.25% | 3,071,615 | – | – |
|
21
Penumbra
PEN
$10.6B
| $54.7M | 1.23% | 204,517 -33,536 | -14% | -$8.97M |
|
|
22
Akero Therapeutics
AKRO
$3.74B
| $50.6M | 1.13% | +1,250,666 | New | +$50.6M |
|
23
Biohaven
BHVN
$1.63B
| $49.1M | 1.1% | 2,040,853 | – | – |
|
|
24
Beam Therapeutics
BEAM
$1.66B
| $46.8M | 1.05% | 2,395,930 +877,809 | +58% | +$17.1M |
|
25
Moderna
MRNA
$9.37B
| $43M | 0.96% | 1,518,122 -82,755 | -5% | -$2.35M |
|